冠脉内成像指导PCI:随机试验更新荟萃分析
该更新荟萃分析纳入28项随机对照试验共24634例患者,比较冠脉内成像(ICI)指导与造影指导的经皮冠状动脉介入治疗(PCI)。结果显示ICI指导PCI显著降低靶病变失败、心源性死亡、心肌梗死、靶血管血运重建、支架血栓及全因死亡风险。
要点
- ICI指导PCI显著降低靶病变失败(RR 0.72)和支架血栓(RR 0.55)。
- 心源性死亡(RR 0.73)和全因死亡(RR 0.82)均显著降低。
- 试验间地理和病变特征差异解释大部分异质性。
核心结论
- 在药物洗脱支架时代,ICI指导PCI较造影指导显著降低心血管事件风险。
研究设计与样本
- 纳入28项随机对照试验,共24634例患者(平均年龄64.8岁,75.9%男性),平均随访22个月。
主要发现
- ICI指导PCI降低靶病变失败(RR 0.72;95%CI 0.61-0.85;I2=61%)。
- 降低心源性死亡(RR 0.73;95%CI 0.58-0.91;I2=5%)和心肌梗死(RR 0.86;95%CI 0.75-0.97;I2=0%)。
- 降低靶血管血运重建(RR 0.69;95%CI 0.57-0.83;I2=41%)、支架血栓(RR 0.55;95%CI 0.40-0.76;I2=0%)和全因死亡(RR 0.82;95%CI 0.70-0.96;I2=0%)。
- 试验序贯分析证实至少20%的降低,脆弱指数9-50,贝叶斯后验获益概率>99%。
关键数值与推荐
- 指南对复杂或左主干病变PCI给予ICI指导I类推荐,但近期试验未显示获益。
临床怎么用
- 对于复杂或左主干病变PCI,可考虑使用ICI指导以降低靶病变失败和支架血栓风险。
- 需结合病变特征和操作技术差异理解试验间异质性。
局限性
- 试验间异质性部分存在(如靶病变失败I2=61%),地理和病变特征差异解释大部分方差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent societal guidelines provide a Class I recommendation for intracoronary imaging (ICI)-guided percutaneous coronary intervention (PCI) for complex or left main coronary artery disease; however, recent trials have failed to show a benefit. OBJECTIVES: The study aim was to re-evaluate the efficacy of ICI-guided PCI and to explore heterogeneity of results across trials. METHODS: PubMed, Embase, Cochrane Central, and ClinicalTrials.gov databases were searched through June 3, 2026, for randomized controlled trials (RCTs) comparing outcomes with ICI-guided PCI vs angiography-guided PCI in the drug-eluting stent era. Direct comparison meta-analyses, mixed treatment comparison meta-analyses, trial sequential analyses, fragility analysis, and Bayesian meta-analyses were performed. Meta-regression analysis was performed to evaluate heterogeneity using the following variables: stent length (surrogate for lesion length), stent diameter, difference in postdilatation (percentage) between the groups, publication year, and geographic location. RESULTS: A total of 28 RCTs met the inclusion criteria, comprising 24,634 patients (mean age 64.8 years; 75.9% male) with a mean follow-up of 22 months. ICI-guided PCI reduced target lesion failure (relative risk [RR]: 0.72; 95% CI: 0.61-0.85; I2 = 61%), cardiac mortality (RR: 0.73; 0.58-0.91; I2 = 5%), myocardial infarction (RR: 0.86; 0.75-0.97; I2 = 0%), target vessel revascularization (RR: 0.69; 95% CI: 0.57-0.83, I2 = 41%), stent thrombosis (RR: 0.55; 95% CI: 0.40-0.76; I2 = 0%), and all-cause mortality (RR: 0.82; 95% CI: 0.70-0.96; I2 = 0%) compared with angiography-guided PCI. Trial sequential analysis confirmed evidence for at least a 20% reduction in all outcomes with ICI-guided PCI. The fragility index was robust, ranging from 9 to 50. The posterior probability for benefit was >99% for all outcomes. Trial differences in geography and lesion characteristics explained most of the between-trial variance (residual tau = 0). CONCLUSIONS: In this updated meta-analysis of RCTs, after accounting for modifier effects from recent studies, ICI-guided PCI was associated with significantly reduced cardiovascular events compared with angiography-guided PCI. Geographic heterogeneity across trials was present mainly for target vessel revascularization, explained in large part by differences in lesion characteristics and procedural technique.
引用
- Bangalore S, Maqsood MH, Zhang RS, et al. Intracoronary Imaging-Guided Percutaneous Coronary Intervention: An Updated Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2026. PMID: 42747372. doi:10.1016/j.jacc.2026.08.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。